Role of acyl-coenzyme A: cholesterol transferase 1 (ACAT1) in retinal neovascularization

被引:6
|
作者
Zaidi, Syed A. H. [1 ,2 ]
Lemtalsi, Tahira [1 ,2 ]
Xu, Zhimin [1 ,2 ]
Santana, Isabella [1 ]
Sandow, Porsche [2 ,3 ]
Labazi, Leila [1 ]
Caldwell, Robert W. [2 ,3 ]
Caldwell, Ruth B. [1 ,2 ,4 ]
Rojas, Modesto A. [1 ,2 ,3 ]
机构
[1] Augusta Univ, Vasc Biol Ctr, 1460 Laney Walker Blvd, Augusta, GA 30912 USA
[2] Augusta Univ, Culver Vis Discovery Inst, Augusta, GA 30912 USA
[3] Augusta Univ, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
[4] Augusta Univ, Dept Cellular Biol & Anat, Augusta, GA 30912 USA
关键词
Hypoxia; Neovascularization; LDL cholesterol; Cholesterol ester; ACAT1; TREM1; Inflammation; Cytokines; Retinopathy of prematurity; Oxygen-induced retinopathy; DIABETIC-RETINOPATHY; OXIDATION; TREM-1; LDL;
D O I
10.1186/s12974-023-02700-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundWe have investigated the efficacy of a new strategy to limit pathological retinal neovascularization (RNV) during ischemic retinopathy by targeting the cholesterol metabolizing enzyme acyl-coenzyme A: cholesterol transferase 1 (ACAT1). Dyslipidemia and cholesterol accumulation have been strongly implicated in promoting subretinal NV. However, little is known about the role of cholesterol metabolism in RNV. Here, we tested the effects of inhibiting ACAT1 on pathological RNV in the mouse model of oxygen-induced retinopathy (OIR).MethodsIn vivo studies used knockout mice that lack the receptor for LDL cholesterol (LDLR-/-) and wild-type mice. The wild-type mice were treated with a specific inhibitor of ACAT1, K604 (10 mg/kg, i.p) or vehicle (PBS) during OIR. In vitro studies used human microglia exposed to oxygen-glucose deprivation (OGD) and treated with the ACAT1 inhibitor (1 mu M) or PBS.ResultsAnalysis of OIR retinas showed that increased expression of inflammatory mediators and pathological RNV were associated with significant increases in expression of the LDLR, increased accumulation of neutral lipids, and formation of toxic levels of cholesterol ester (CE). Deletion of the LDLR completely blocked OIR-induced RNV and significantly reduced the AVA. The OIR-induced increase in CE formation was accompanied by significant increases in expression of ACAT1, VEGF and inflammatory factors (TREM1 and MCSF) (p < 0.05). ACAT1 was co-localized with TREM1, MCSF, and macrophage/microglia makers (F4/80 and Iba1) in areas of RNV. Treatment with K604 prevented retinal accumulation of neutral lipids and CE formation, inhibited RNV, and decreased the AVA as compared to controls (p < 0.05). The treatment also blocked upregulation of LDLR, ACAT1, TREM1, MCSF, and inflammatory cytokines but did not alter VEGF expression. K604 treatment of microglia cells also blocked the effects of OGD in increasing expression of ACAT1, TREM1, and MCSF without altering VEGF expression.ConclusionsOIR-induced RNV is closely associated with increases in lipid accumulation and CE formation along with increased expression of LDLR, ACAT1, TREM1, and MCSF. Inhibiting ACAT1 blocked these effects and limited RNV independently of alterations in VEGF expression. This pathway offers a novel strategy to limit vascular injury during ischemic retinopathy.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Role of acyl-coenzyme A: cholesterol transferase 1 (ACAT1) in retinal neovascularization
    Syed A. H. Zaidi
    Tahira Lemtalsi
    Zhimin Xu
    Isabella Santana
    Porsche Sandow
    Leila Labazi
    Robert W. Caldwell
    Ruth B. Caldwell
    Modesto A. Rojas
    Journal of Neuroinflammation, 20
  • [2] Role of acyl-coenzyme A: cholesterol transferase (ACAT1) in pathological angiogenesis
    Rojas, Modesto Antonio
    Santana, Isabella
    Lemtalsi, Tahira
    Caldwell, William
    Caldwell, Ruth B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [3] Novel role of acyl-coenzyme A: cholesterol transferase (ACAT1) in ischemic retinopathy
    Rojas, Modesto Antonio
    Lemtalsi, Tahira
    Santana, Isabella
    Caldwell, Robert W.
    Caldwell, Ruth B.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [4] Is acyl-coenzyme A: cholesterol transferase (ACAT1) a mediator of neurovascular injury in diabetic retinopathy?
    Rojas, Modesto
    Zaidi, Syed
    Lemtalsi, Tahira
    Xu, Zhimin
    Sandow, Porsche
    Caldwell, R.
    Caldwell, Ruth
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [5] A catalytically active mutant acyl-coenzyme A: Cholesterol acyltransferase 1 (ACAT1) devoid of cysteine residues
    Lu, XH
    Chang, CCY
    Lin, S
    Chang, TY
    CIRCULATION, 2001, 104 (17) : 233 - 233
  • [6] Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs
    Leon, C
    Hill, JS
    Wasan, KM
    PHARMACEUTICAL RESEARCH, 2005, 22 (10) : 1578 - 1588
  • [7] Potential Role of Acyl-Coenzyme A:Cholesterol Transferase (ACAT) Inhibitors as Hypolipidemic and Antiatherosclerosis Drugs
    Carlos Leon
    John S. Hill
    Kishor M. Wasan
    Pharmaceutical Research, 2005, 22 : 1578 - 1588
  • [8] Role of acyl-coenzyme A: Cholesterol acyltransferase (ACAT) in cholesterol gallstone pathogenesis
    Smith, JL
    Rangaraj, K
    Scott, SP
    Maclean, DJ
    de Jersey, J
    ATHEROSCLEROSIS: RISK FACTORS, DIAGNOSIS, AND TREATMENT, 2002, : 1 - 7
  • [9] Human acyl-coenzyme A:cholesterol acyltransferase 1 (acat1) sequences located in two different chromosomes (7 and 1) are required to produce a novel ACAT1 isoenzyme with additional sequence at the N terminus
    Yang, L
    Lee, O
    Chen, J
    Chen, J
    Chang, CCY
    Zhou, P
    Wang, ZZ
    Ma, HH
    Sha, HF
    Feng, JX
    Wang, Y
    Yang, XY
    Wang, L
    Dong, RH
    Ornvold, K
    Li, BL
    Chang, TY
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (44) : 46253 - 46262
  • [10] POTENT, SELECTIVE, AND SYSTEMICALLY-AVAILABLE INHIBITORS OF ACYL-COENZYME A-CHOLESTEROL ACYL TRANSFERASE (ACAT)
    MCCARTHY, PA
    HAMANAKA, ES
    MARZETTA, CA
    BAMBERGER, MJ
    GAYNOR, BJ
    CHANG, G
    KELLY, SE
    INSKEEP, PB
    MAYNE, JT
    BEYER, TA
    WALKER, FJ
    GOLDBERG, DI
    SAVOY, YE
    DAVIS, KM
    DIAZ, CL
    FREEMAN, AM
    JOHNSON, DA
    LACOUR, TG
    LONG, CA
    MALONEY, ME
    MARTINGANO, RJ
    PETTINI, JL
    SAND, TM
    WINT, LT
    JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (09) : 1252 - 1255